Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists

Trends in Pharmacological Sciences

Volumn 20, Issue 12, 1999, Pages 485-490

  Rupniak, Nadia M J ^a   Kramer, Mark S ^b,c  

^a MSDNRC   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 [3,5 BIS(TRIFLUOROMETHYL)PHENYL]ETHOXY] 3 (4 FLUOROPHENYL) 4 (3 OXO 1 PHOSPHORYL 1,2,4 TRIAZOL 5 YLMETHYL)MORPHOLINE; 3 (2 METHOXY 5 TRIFLUOROMETHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 3 (2 METHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; APREPITANT; HALOPERIDOL; LANEPITANT; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROTRANSMITTER; RECEPTOR SUBTYPE; RP 100893; SUBSTANCE P; SUBSTANCE P RECEPTOR; TACHYKININ RECEPTOR; UNCLASSIFIED DRUG; VOFOPITANT;

AFFECTIVE NEUROSIS; ANALGESIC ACTIVITY; ANIMAL MODEL; ANTIEMETIC ACTIVITY; BEHAVIOR; CARDIOVASCULAR RESPONSE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; HUMAN; MENTAL DISEASE; NEUROCHEMISTRY; NONHUMAN; PAIN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; STRESS; TISSUE DISTRIBUTION; TOOTH PAIN; VOMITING;

ANTIDEPRESSIVE AGENTS; ANTIEMETICS; BEHAVIOR; CARDIOVASCULAR SYSTEM; CLINICAL TRIALS; HUMANS; LIGANDS; NEUROTRANSMITTER AGENTS; PAIN; RECEPTORS, NEUROKININ-1;

EID: 0033457351     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(99)01396-6     Document Type: Review

References (53)

1. Kramer M.S.et al. Science. 281:1998;1640-1645.
2. Quartara L., Maggi C.A. Neuropeptides. 32:1998;1-49.
3. Snider R.M.et al. Science. 251:1991;435-437.
4. Beresford I.J.M.et al. Br. J. Pharmacol. 104:1991;292-293.
5. Rupniak N.M.J.et al. Eur. J. Pharmacol. 326:1997;201-209.
6. Rupniak N.M.J.et al. Br. J. Pharmacol. 110:1993;1607-1613.
7. Rupniak N.M.J., Hill R.G. Sawynok J., Cowan A. Novel Aspects of Pain Management: Opioids and Beyond. 1999;135-155 John Wiley Press.
8. Lembeck F. Arch. Exp. Path. Pharmacol. 219:1953;197-213.
9. Chang M.M.et al. Nature New Biol. 232:1971;86-88.
10. Henry J.L. Brain Res. 114:1976;439-451.
11. Hokfelt T.et al. Brain Res. 100:1975;235-252.
12. Duggan A.W.et al. Brain Res. 403:1987;345-349.
13. Shults C.W.et al. Peptides. 5:1984;1097-1128.
14. de Koninck Y., Henry J.L. Proc. Natl. Acad. Sci. U. S. A. 88:1991;11344-11348.
15. Block G.A.et al. Neurology. 50:1998;A225.
16. Kramer M.S.et al. Biol. Psychiatry. 37:1995;462-466.
17. Armstrong D.M.et al. J. Comp. Neurol. 196:1981;505-517.
18. 3 Receptor Antagonists. 1994;255-317 CRC Press.
19. Matsumoto S.et al. Gan To Kagaku Ryoho. 26:1999;535-538.
20. Tattersall F.D.et al. Neuropharmacology. 33:1994;259-260.
21. Tattersall F.D.et al. Neuropharmacology. 35:1996;1121-1129.
22. Rudd J.A., Jordan C.C., Naylor R.J. Br. J. Pharmacol. 119:1996;931-936.
23. Kris M.G.et al. J. Natl. Cancer Inst. 89:1997;817-818.
24. Hesketh P.J.et al. J. Clin. Oncol. 17:1999;338-343.
25. Navari R.M.et al. New Engl. J. Med. 340:1999;190-195.
26. Tamiya R.et al. Neurosci. Lett. 110:1990;11-15.
27. Elliott P.J.et al. Neuropeptides. 19:1991;119-123.
28. Elliott P.J.et al. Behav. Brain Res. 51:1992;77-82.
29. Elliott P.J., Nemeroff C.B., Kilts C.D. Brain Res. 385:1986;379-382.
30. Minabe Y.et al. Synapse. 22:1996;35-45.
31. Seabrook G.R., Bowery B.J., Hill R.G. Eur. J. Pharmacol. 273:1995;113-119.
32. Whitty C.J., Paul M.A., Bannon M.J. J. Comp. Neurol. 382:1997;394-400.
33. Shibata K., Haverstick D.M., Bannon M.J. J. Pharmacol. Exp. Ther. 255:1990;388-392.
34. Miller C.et al. Biol. Psychiatry. 39:1996;911-918.
35. Gabbard G. Kaplan B., Saddock E.S. Comprehensive Textbook of Psychiatry VI. 1995;465 Williams and Wilkins.
36. Mantyh P.W., Hunt S.P., Maggio J.E. Brain Res. 307:1984;147-165.
37. Baker K.G.et al. Neuroscience. 42:1991;757-775.
38. Elliott P.J. Exp. Brain Res. 381:1988;354-356.
39. Aguiar M.S., Brandao M.L. Physiol. Behav. 60:1996;1183-1186.
40. Krase W., Koch M., Schnizler H-U. Behav. Brain Res. 63:1994;81-88.
41. Culman J., Unger T. Can. J. Physiol. Pharmacol. 73:1995;885-891.
42. Brodin E.et al. Neuropeptides. 26:1994;253-260.
43. Siegel R.A.et al. Neurochem. Int. 6:1984;783-789.
44. Shirayama Y.et al. Brain Res. 739:1996;70-78.
45. Berrettini W.H.et al. Biol. Psychiatry. 20:1985;965-968.
46. Bannon M.J.et al. Nature. 306:1986;791-792.
47. Barton C.L.et al. Br. J. Pharmacol. 126:1999;284P.
48. Hahn M.K., Bannon M.J. Neuroscience. 1999;. (in press).
49. Zernig G.et al. Neurosci. Lett. 143:1992;169-172.
50. File S.E. Pharmacol. Biochem. Behav. 58:1997;747-752.
51. Shaikh M.B., Steinberg A., Siegel A. Brain Res. 625:1993;283-290.
52. Dubinsky B., Goldberg M.E. Neuropharmacology. 10:1971;537-542.
53. Williams M. Inv. Drugs. 1:1998;887-889.